Skip to main content
. 2001 Jun 15;7(3):411–414. doi: 10.3748/wjg.v7.i3.411

Table 2.

Responses to treatment at the end of follow-up n (%)

T-a1 (n = 18)
IFN-α (n = 33)
HC (n = 30)
(after 12 mo of follow-up)
ALT normalization 11 (61.1)a 10 (30.3) 3 (10)
HBV DNA-negative 13 (72.2)ab 13 (39.4)b 2 (6.7)
ALT normal/HBV DNA and HBeAg-negative 10 (55.6)ab 9 (27.3) 1 (3.3)
a

P < 0.05, vs IFN-α;

b

P < 0.01, vs HC.